GH1 and cancer: In the absence of safety data, it was the consensus of the panel that it would be reasonable to delay the onset of GH replacement until patients with these conditions are in remission for 5 or more years (see further the section ‘How long should providers wait between completion of therapy for cancer or intracranial tumour and the initiation of GH therapy’)?